سعر موكسيسيارو بلس 0.5% قطرة للعين 5مل 2025

Moxyseyaro Plus eye drops 5 ml (Rameda > Talent Pharma, Egypt): sterile ophthalmic solution combining moxifloxacin 0.5% (fluoroquinolone antibacterial) with dexamethasone phosphate 0.1% (corticosteroid).

• Moxifloxacin eye drops: conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, hyperemia, pain, pruritus, subconjunctival hemorrhage and tearing (about 1%-6%).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Dexamethasone eye drops: glaucoma with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract, secondary ocular infection (including herpes simplex), perforation of the globe; rarely stinging or burning.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to moxifloxacin, other quinolones or any component (moxifloxacin component).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Epithelial herpes simplex keratitis (dendritic keratitis); acute infectious stages of vaccinia, varicella and many other viral diseases of the cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases of ocular structures; hypersensitivity to any component (dexamethasone component).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Serious hypersensitivity (anaphylactic) reactions have been reported with systemic quinolones including moxifloxacin; prolonged use may cause overgrowth of non-susceptible organisms including fungi; avoid contact lenses during bacterial conjunctivitis.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Prolonged corticosteroid use may cause ocular hypertension and/or glaucoma with optic nerve damage, visual acuity and field defects, and posterior subcapsular cataract; it may suppress host response and increase the risk of secondary ocular infection; perforation may occur in diseases that thin the cornea or sclera; corticosteroids may mask or enhance acute purulent infection.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Persistent fungal infection of the cornea should be considered after prolonged corticosteroid dosing.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Drugs metabolised by major CYP450 isozymesMoxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19 or CYP1A2 in vitro; no interaction studies with the eye drops.DailyMed (U.S. National Library of Medicine)

• Moxifloxacin: no adequate studies in pregnant women; no adverse fetal effects in animal studies at clinically relevant doses.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Dexamethasone: teratogenic in mice and rabbits after topical ophthalmic application in multiples of the therapeutic dose; no adequate human studies; use in pregnancy only if the potential benefit justifies the potential risk to the fetus.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Moxifloxacin: no human milk data; low systemic levels after ocular use.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Dexamethasone: topically applied steroids are absorbed systemically; decide whether to discontinue nursing or the drug, considering the importance of the drug to the mother.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• If a topical ophthalmic corticosteroid is used for 10 days or longer, intraocular pressure should be monitored routinely.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Moxifloxacin: Inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair and chromosome partitioning.
• Dexamethasone phosphate: Corticosteroid that suppresses the inflammatory response to a variety of agents and probably delays or slows healing (US dexamethasone ophthalmic label).